Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of multispecific modalities across its areas of therapeutic focus.
The French pharma, which had been test driving the platform under a July 2017 deal, also could be in a position to more broadly exploit the platform than Ablynx could have done as a stand-alone company.
“I am focused on developing Nanobodies and using this technology in the best, most effective way possible,” Ablynx CEO Edwin Moses told BioCentury. “And I’m convinced Sanofi can do that quicker and better than we could have ever done as an independent organization on our own.”
That reality represents a pivot from the end of 2017, when, having filed for its first product in Europe, Ablynx had every intention of growing as an independent company.
In October, it reported positive data from the Phase